Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Transgenomic and NYU Collaborate on Lung Cancer Study

Published: Wednesday, September 05, 2012
Last Updated: Wednesday, September 05, 2012
Bookmark and Share
Research set to use ICE COLD-PCR for blood-based mutation detection.

Transgenomic, Inc. announced that it has begun a collaboration with NYU Langone Medical Center to employ its ultra-high sensitivity ICE COLD-PCR mutation detection technology to better understand molecular events that drive non-small cell lung cancer and impact response to existing and novel therapies. The joint study will focus on the detection of cancer-associated mutations in the blood of patients with surgically operable early stage lung cancer, the stage where it is most curable and amenable to treatment.

Rare circulating tumor cells (CTCs) will be isolated from the blood of approximately 200 patients using Transgenomic's licensed CTC capture ScreenCell® devices before and following surgery to determine if the numbers of CTCs change in response to treatment or are associated with disease recurrence or progression. DNA from these cells will be analyzed by ICE COLD-PCR for the presence of mutations that have been shown to affect response to targeted drugs; tumor-derived cell-free DNA (cfDNA) found in blood samples will be analyzed similarly. The molecular profile of cfDNA and DNA isolated from CTCs will then be compared to that of the primary lung tumor to better understand characteristics of cells that escape the tumor and are thought to be responsible for metastasis. Mutations conferring drug resistance can also be measured from CTCs and cfDNA and may indicate the re-emergence of disease before clinical symptoms appear, at a time when the administration of alternative therapies may forestall progression.

"Our ICE COLD-PCR technology is ideally suited to monitor patients' disease activity and response to drugs in real time", said Craig Tuttle, Chief Executive Officer of Transgenomic, Inc. "Detecting cancer mutations from CTCs and DNA present in blood samples will allow physicians to intervene before clinical symptoms of disease recurrence appear and make routine 'blood biopsies' a reality."

The study will be jointly overseen by Dr. Harvey I. Pass, M.D., the Stephen E. Banner Professor of Thoracic Oncology and Vice-Chair Research, Department of Cardiothoracic Surgery and Division Chief, General Thoracic Surgery, NYU Langone Medical Center, and by Drs. Marcia Lewis, Vice President of Biomarker Development and Katherine Richardson, Vice President of R&D at Transgenomic, Inc. Transgenomic will provide funding for support staff at NYU Langone Medical Center for the duration of the study, which is estimated to take between one and two years.

"The NYU Langone Thoracic Oncology Laboratory is extremely excited about this collaboration, which was facilitated by the Early Detection Research Network of the NCI/NIH", said Dr. Pass. "It will enable a greater understanding of the role of CTCs in early lung cancer in a prospectively accrued, large number of patients. Moreover, the ability to detect tumor-identical mutations in CTCs from lung cancer patients could open up a wealth of possibilities for non-invasively prescribing the appropriate therapy for the right patient, especially now when so many targetable mutations are being discovered in the disease."

This study builds on Transgenomic's recently announced collaboration at MD Anderson Cancer Center that also employs ICE COLD-PCR to characterize tumor-derived DNA in blood and DNA isolated from CTCs from patients with a variety of cancers to choose therapies shown to target specific mutations. Transgenomic is negotiating additional collaborations at major cancer centers in the US to extend the validation of its ICE COLD-PCR technology.

In June, the Company announced the commercial launch of its REVEAL® Kits which utilize ICE COLD-PCR to detect mutations in a variety of cancer-associated genes.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Transgenomic Awarded NIH Grant
STTR grant supports addition of greater multiplexing capabilities to ICE COLD-PCR, an advanced technology that enables use of tissue or liquid biopsy samples and provides up to 500-fold increase in mutation detection on any sequencing platform.
Monday, January 04, 2016
Transgenomic Licenses Liquid Biopsy Technology to University of Melbourne
Commercial agreement for Australia allows University of Melbourne to use Transgenomic’s multiplexed ICE COLD-PCR™ product for cancer diagnostics and biomarker identification.
Friday, September 18, 2015
Transgenomic Expands License Agreement With Exiqon
Access to Exiqon’s LNA Oligos enhances multiplexed ICE COLD-PCR’s ultra-sensitive detection of cancer mutations in both tissue and liquid biopsies.
Wednesday, March 18, 2015
Transgenomic Announces $2.375 Million Private Placement Financing
Net proceeds from this offering will support Company’s ICE COLD-PCR™ technology.
Tuesday, October 28, 2014
Transgenomic Licenses Exclusive Rights to Multiplexed Ice Cold-PCRTM Technology
Multiplexed Version of Revolutionary Technology Enables Efficient Detection of Multiple Cancer Mutations in a Single Liquid Assay
Wednesday, May 28, 2014
Transgenomic, Raptor to Collaborate
Transgenomic to provide genetic profiling for Raptor's clinical trial evaluating drug for the treatment of Leigh Syndrome and other mitochondrial disorders.
Friday, April 04, 2014
Transgenomic Awarded NIH STTR Grant for Pancreatic Cancer Research
Transgenomic, Inc. has been awarded a $100,000 Small Business Technology Transfer Program Phase I Grant by the NIH’s National Center For Advancing Translational Sciences.
Wednesday, August 22, 2012
Transgenomic and ScreenCell Announce Worldwide Distribution and Collaboration Agreement
The perpetual, worldwide collaboration and distribution agreement is for ScreenCell’s Isolation Devices and Dilution Buffers.
Wednesday, November 09, 2011
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Genetic Tug of War Before Cells Decide Fate
Researchers report that as developing blood cells are triggered by genetic signals firing on and off, a 'tug of war' occurs.
$1M NIH Grant to Refine PCR Based Cancer Test
Researchers at Cornell University, Weill Cornell Medicine, the University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda, recieve a four-year, $1 million grant to hone technology for a quick, in-the-field diagnosis of Kaposi's sarcoma — a cancer frequently related to HIV infections.
Linkage Biosciences Awarded NHS Contract
Comapny announces that it has been awarded a four-year contract by NHS Blood and Transplant (NHSBT) in the UK for implementation of the LinkSeq™ Real-Time PCR HLA typing product.
Understanding Tumor Evolution
Study provides insight into tumor evolution; may point to improved diagnosis and treatment.
Frankfurter Fraud: Finding Out What’s In Your Hot Dog
Scientists have developed a technique to test the meat content of Frankfurters.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Keeping Cells in Shape to Fight Sepsis
Boosting levels of a protein that controls the shape and activity of a crucial group of white blood cells improves survival and recovery chances during sepsis.
This 3D Printer Can Detect Infectious Diseases
Researchers at AI Biosciences, Inc. have repurposed 3D printers into machines capable of performing sample preparation and DNA amplification.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!